Faes Farma, S.A. (FAE.MC)
EUR 4.31
(0.94%)
EUR 4.31
(0.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 122.93 Million EUR | 1.45% |
| 2022 | 121.35 Million EUR | 5.95% |
| 2021 | 110.83 Million EUR | 8.58% |
| 2020 | 100.26 Million EUR | 15.44% |
| 2019 | 87.21 Million EUR | 26.0% |
| 2018 | 72.46 Million EUR | 27.87% |
| 2017 | 58.38 Million EUR | 5.88% |
| 2016 | 52.23 Million EUR | 12.64% |
| 2015 | 45.39 Million EUR | 11.86% |
| 2014 | 40.04 Million EUR | 17.32% |
| 2013 | 33.47 Million EUR | 16.3% |
| 2012 | 29.86 Million EUR | 30.13% |
| 2011 | 23.66 Million EUR | -25.84% |
| 2010 | 32.32 Million EUR | 63.94% |
| 2009 | 30.08 Million EUR | -44.51% |
| 2008 | 31.27 Million EUR | -1.49% |
| 2007 | 36.83 Million EUR | 59.26% |
| 2006 | 39.82 Million EUR | -0.47% |
| 2005 | 22.75 Million EUR | -52.19% |
| 2004 | 47.59 Million EUR | 17.62% |
| 2003 | 40.46 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 42.59 Million EUR | 6.9% |
| 2024 Q1 | 40.96 Million EUR | -21.61% |
| 2023 FY | - EUR | 1.45% |
| 2023 Q3 | 29.43 Million EUR | -15.04% |
| 2023 Q4 | 45.7 Million EUR | 55.27% |
| 2023 Q1 | 37.15 Million EUR | 82.87% |
| 2023 Q2 | 34.64 Million EUR | -6.75% |
| 2022 Q2 | 35.49 Million EUR | -1.19% |
| 2022 Q3 | 29.22 Million EUR | -17.66% |
| 2022 Q4 | 20.31 Million EUR | -30.47% |
| 2022 Q1 | 35.91 Million EUR | 133.82% |
| 2022 FY | - EUR | 5.95% |
| 2021 Q2 | 33.37 Million EUR | 11.77% |
| 2021 FY | - EUR | 8.58% |
| 2021 Q4 | 15.36 Million EUR | -51.75% |
| 2021 Q3 | 31.84 Million EUR | -4.6% |
| 2021 Q1 | 29.86 Million EUR | 257.19% |
| 2020 FY | - EUR | 15.44% |
| 2020 Q1 | 30.34 Million EUR | -89.22% |
| 2020 Q2 | 29.08 Million EUR | -4.14% |
| 2020 Q3 | 29.42 Million EUR | 1.17% |
| 2020 Q4 | 8.36 Million EUR | -71.59% |
| 2019 Q3 | -244.4 Million EUR | -319.65% |
| 2019 Q2 | 111.27 Million EUR | 267.55% |
| 2019 FY | - EUR | 26.0% |
| 2019 Q1 | -66.4 Million EUR | -468.1% |
| 2019 Q4 | 281.6 Million EUR | 215.22% |
| 2018 Q2 | 20.15 Million EUR | 12.6% |
| 2018 Q4 | 18.04 Million EUR | 11.74% |
| 2018 FY | - EUR | 27.87% |
| 2018 Q1 | 17.9 Million EUR | 24.51% |
| 2018 Q3 | 16.14 Million EUR | -19.9% |
| 2017 Q3 | 14.27 Million EUR | -8.65% |
| 2017 FY | - EUR | 5.88% |
| 2017 Q1 | 13.9 Million EUR | 45.98% |
| 2017 Q4 | 14.37 Million EUR | 0.71% |
| 2017 Q2 | 15.62 Million EUR | 12.42% |
| 2016 FY | - EUR | 12.64% |
| 2016 Q4 | 9.52 Million EUR | -43.21% |
| 2016 Q3 | 16.76 Million EUR | -75.85% |
| 2016 Q2 | 69.43 Million EUR | 257.8% |
| 2016 Q1 | -44 Million EUR | -127.22% |
| 2015 Q2 | 62.9 Million EUR | 256.87% |
| 2015 Q3 | -139.29 Million EUR | -321.45% |
| 2015 Q4 | 161.65 Million EUR | 216.05% |
| 2015 FY | - EUR | 11.86% |
| 2015 Q1 | -40.1 Million EUR | -751.4% |
| 2014 Q3 | 14.97 Million EUR | 40.03% |
| 2014 Q4 | 6.15 Million EUR | -58.9% |
| 2014 Q2 | 10.69 Million EUR | 11.17% |
| 2014 FY | - EUR | 17.32% |
| 2014 Q1 | 9.62 Million EUR | 573.74% |
| 2013 Q2 | 7.88 Million EUR | -22.95% |
| 2013 Q3 | 15.17 Million EUR | 92.34% |
| 2013 Q4 | 1.42 Million EUR | -90.59% |
| 2013 FY | - EUR | 16.3% |
| 2013 Q1 | 10.23 Million EUR | 363.05% |
| 2012 Q1 | 8.61 Million EUR | 877.98% |
| 2012 Q3 | 13.01 Million EUR | 116.32% |
| 2012 FY | - EUR | 30.13% |
| 2012 Q4 | 2.21 Million EUR | -83.01% |
| 2012 Q2 | 6.01 Million EUR | -30.16% |
| 2011 Q1 | 11.24 Million EUR | 0.0% |
| 2011 Q4 | 881 Thousand EUR | -87.63% |
| 2011 Q3 | 7.12 Million EUR | 50.78% |
| 2011 FY | - EUR | -25.84% |
| 2011 Q2 | 4.72 Million EUR | -57.98% |
| 2010 Q1 | 11.6 Million EUR | 0.0% |
| 2010 FY | - EUR | 63.94% |
| 2010 Q2 | 8.12 Million EUR | -29.96% |
| 2009 FY | - EUR | -44.51% |
| 2008 FY | - EUR | -1.49% |
| 2007 FY | - EUR | 59.26% |
| 2006 FY | - EUR | -0.47% |
| 2005 FY | - EUR | -52.19% |
| 2004 FY | - EUR | 17.62% |
| 2003 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Almirall, S.A. | 122.51 Million EUR | -0.344% |
| Laboratorio Reig Jofre, S.A. | 35.13 Million EUR | -249.88% |